A Safety, Pharmacokinetics and Pharmacodynamics Study of GNR-086 and Ilaris® in Healthy Volunteers

NCT ID: NCT06481189

Last Updated: 2024-07-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 105 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-09-06
• Study Completion Date: 2023-05-26

Brief Summary

This is a randomized single-blind comparative parallel group study of the safety, pharmacokinetics and pharmacodynamics of GNR-086 and Ilaris® in healthy volunteers. Participants received a single subcutaneous dose of canakinumab 150 mg. The follow up period was 120 days.

Detailed Description

GNR-086 (canakinumab) is being developed as a biosimilar to the drug Ilaris®, a lyophilisate for the preparation of solution for subcutaneous administration.

Canakinumab is a recombinant human monoclonal antibody against human interleukine-1β that belongs to the immunoglobulin G1/k (IgG1/k) isotype subclass.

This study is intended for a comparative study of the safety, pharmacokinetics and pharmacodynamics of the drug GNR-086 and the reference drug Ilaris® for the purpose of registration of the drug - GNR-086 (JSC GENERIUM, Russia), 150 mg, lyophilisate for the preparation of solution for subcutaneous administration in the Russian Federation. The study included healthy volunteers aged 18-45 years at the time of signing the informed consent form. The study included a screening period, single administration of study/comparator drug and a follow up period. Allocation of patients to treatment groups was carried out by randomization in a ratio of 1:1 to the study drug and comparator drug. 105 patients (53 to the study drug group and 52 to the comparator drug group) were randomized.

Conditions

Healthy Volunteers

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: SINGLE

Study Groups

GNR-086 (JSC "GENERIUM", Russia)

canakinumab biosimilar

Group Type: EXPERIMENTAL

GNR-086

Intervention Type: BIOLOGICAL

The test drug GNR-086 was administered as a subcutaneous injection at a single dose of 150 mg.

Ilaris® (Novartis Pharma Stein AG, Switzerland)

canakinumab

Group Type: ACTIVE_COMPARATOR

Ilaris®

Intervention Type: BIOLOGICAL

The reference drug Ilaris® was administered as a subcutaneous injection at a single dose of 150 mg.

Interventions

GNR-086

The test drug GNR-086 was administered as a subcutaneous injection at a single dose of 150 mg.

Intervention Type: BIOLOGICAL

Ilaris®

The reference drug Ilaris® was administered as a subcutaneous injection at a single dose of 150 mg.

Intervention Type: BIOLOGICAL

Other Intervention Names

canakinumab; canakinumab

Eligibility Criteria

Inclusion Criteria

• Written informed consent to participate in the study, obtained from the volunteer before the start of any procedures related to the study;
• Men and women aged 18 to 45 years, inclusive, at the time of signing the informed consent form;
• Verified diagnosis "healthy" (the diagnosis "healthy" is established on the basis of a detailed medical history, in the absence of deviations from normal values during a clinical examination, including measurement of blood pressure, heart rate, respiratory rate, body temperature, as well as laboratory data studies, results of electrocardiography and fluorography);
• Body weight from 50 to 85 kg, body mass index from 18.5 to 28 kg/m2, inclusive.
• Agreement to adhere to adequate methods of contraception during the entire period of participation in the study or for 3 months after administration of the study or reference drug in case of early termination of participation in the study.

Exclusion Criteria

• Severe chronic diseases, history of seizures;
• Acute infectious diseases less than 4 weeks before administration of the study or reference drug;
• Any history of chronic or recurrent infectious diseases;
• History of tuberculosis;
• Vaccination with any vaccine within 3 months before the administration of the study or reference drug or planned for the period of the volunteer's participation in the study;
• Compounded allergy history; history of hypersensitivity to the active substance or other components of the study or reference drug;
• Pregnancy or breastfeeding period;
• Special lifestyle (work at night, extreme physical activity);
• Deviations of vital signs: systolic pressure less than 100 mm Hg. Art. or more than 130 mm Hg. Art.; diastolic pressure less than 60 mm Hg. Art. or more than 90 mm Hg. Art.; heart rate less than 60 beats/min or more than 90 beats/min;
• Dehydration due to diarrhea, vomiting, or other cause within 24 hours prior to administration of the study or reference drug;
• Taking prescription medications within 28 days or 5 half-lives (whichever is longer) or taking over-the-counter medications/dietary supplements within 14 days prior to study or reference drug administration (occasional use of paracetamol at any time prior to study drug administration is acceptable) or reference drug);
• Blood donation or blood loss (450 ml of blood or more) less than 3 months before the administration of the study or reference drug and/or blood donation in any quantity planned for the period of the volunteer's participation in the study;
• Participation in clinical trials of medicinal products (less than 3 months or 5 half-lives from the study drug, whichever is longer) before administration of the investigational or reference drug of this study;
• Regular alcohol consumption exceeding 5 units. alcohol per week (where each unit is equal to 30 ml of ethyl alcohol or 325 ml of beer), or information about a history of alcoholism, drug addiction, or drug abuse;
• Positive test for the presence of alcohol in exhaled air;
• Smoking more than 5 cigarettes per day for 3 months before this study;
• Positive urine test for the content of narcotic and potent drugs;
• Positive test for hepatitis B, C, HIV or syphilis;
• Any surgical interventions planned during the period of participation in the study;
• Unwillingness or inability to comply with the requirements of this protocol.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

AO GENERIUM

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Oksana A. Markova, MD

Role: STUDY_CHAIR

JSC GENERIUM

Locations

State budgetary healthcare institution of the city of Moscow "City Clinic No. 2 of the Moscow Health Department"

Moscow, , Russia

Federal State Budgetary Educational Institution of Higher Education "Moscow State Medical and Dental University named after A.I. Evdokimov" of the Ministry of Health of the Russian Federation

Moscow, , Russia

Countries

Russia

Other Identifiers

CAN-HVL-I

Identifier Type: -

Identifier Source: org_study_id